Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence

NCT05062096 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
220
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators